Search

A recent study conducted in Rawalpindi, Pakistan, focused on the impact of iron overload on liver function in patients with Beta Thalassemia Major. The research found that patients receiving blood transfusions for Thalassemia major had increased levels of liver enzymes, such as AST, ALT, and bilirubin, associated with high ferritin levels. The study emphasized the importance of regular liver function tests to detect and manage liver damage in Thalassemia patients, ultimately aiming to reduce morbidity and mortality. [Extracted from the article]

The article discusses a study on a liver function test score that can identify high-risk patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) based on the pattern of liver enzymes. The study found that patients with a cholestatic pattern of liver enzymes had a higher incidence of major adverse liver-related outcomes and major adverse cardiovascular events compared to those with a hepatocellular pattern. The newly formulated liver function test score was effective in categorizing patients and may serve as a useful prognostic tool for MASLD patients. [Extracted from the article]

A patent has been issued for a liver activation nanoemulsion and toxin excretion enhancement method by Quicksilver Scientific Inc. The invention aims to enhance liver performance in animals through an intra-oral nanoemulsion blend that includes various components such as milk thistle, diindolylmethane, quercetin, and luteolin. The method involves holding the blend under the tongue, consuming a solid powder toxin binding composition, and excreting the toxins. This patent focuses on improving liver function and detoxification processes through innovative nanoemulsion technology. [Extracted from the article]

The patent application titled "Method For Assessment Of Hepatic Function And Portal Blood Flow" discusses a method for estimating portal blood flow and hepatic function in patients with liver diseases such as chronic hepatitis C, nonalcoholic fatty liver disease (NAFLD), and primary sclerosing cholangitis (PSC). The method involves administering isotopically labeled cholic acid and analyzing a single blood sample to estimate portal blood flow. This non-invasive test aims to provide a simpler and more efficient way to monitor hepatic function and portal blood flow in patients with chronic liver diseases. [Extracted from the article]

Researchers from Jiangxi University conducted a study on the effectiveness and safety of Pueraria lobata radix (Ge Gen)-containing prescriptions for treating nonalcoholic fatty liver disease (NAFLD). The study included 18 randomized controlled trials involving 1,991 patients and found that the group receiving the Ge Gen-containing prescriptions showed significant improvements in liver function, blood lipid levels, body mass index, blood glucose levels, and symptom severity scores. The researchers concluded that Ge Gen-containing prescriptions may be a beneficial adjunct therapy for NAFLD, but noted that the quality of evidence was moderate-to-very low due to bias and heterogeneity. [Extracted from the article]

A study conducted at the Affiliated Hospital of Qingdao University in China focused on the impact of primary biliary cholangitis (PBC) on sleep disturbance and its correlation with mental health and biochemical markers. The research found that poor sleep quality in PBC patients was associated with higher levels of anxiety, depression, and lower albumin levels. The study suggested that evaluating mental health-related indicators in PBC patients is crucial in addition to routine blood tests and imaging. This research provides valuable insights into the relationship between psychological factors, biochemical indicators, and sleep disturbance in patients with primary biliary cholangitis. [Extracted from the article]

A study conducted at Washington University focused on assessing reference intervals for liver enzymes, specifically alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT). The research compared manufacturer's reference intervals to indirectly estimated reference intervals (IRIs) using data from over 200,000 outpatients. The study found moderate agreement and positive correlation between ALP and GGT, with no significant differences between the lower limits of IRIs and current reference intervals. Further investigation is recommended to explore the impact of patient populations on reference intervals. [Extracted from the article]

The article discusses a clinical trial, NCT06647056, evaluating the effect of a single dose of psilocybin on cognitive control in patients with psychogenic nonepileptic seizures (PNES). The study aims to investigate the impact of psilocybin on neural correlates of cognitive control in patients with PNES. Researchers hypothesize that psilocybin may improve cognitive control in these patients. The trial is set to enroll 10 participants and is expected to be completed by August 2026. [Extracted from the article]

The article discusses a study on the impact of HIV and HCV co-infections on liver disease progression in HBV patients, focusing on the use of alpha-fetoprotein (AFP) as a predictor of liver disease. The research found that HBV/HCV co-infected patients had higher AFP levels, indicating an increased risk of liver disease progression and hepatocellular carcinoma. The study highlights the importance of routine AFP and liver function tests for early detection and treatment of liver disease in HBV patients, particularly those with HCV co-infection. [Extracted from the article]

The article discusses a clinical trial, NCT06632444, focusing on the use of survodutide to help individuals with non-alcoholic steatohepatitis (NASH) or metabolic-associated steatohepatitis (MASH) and moderate or advanced liver fibrosis improve their liver function. The study involves two parts, with participants randomly assigned to receive either survodutide or a placebo, injected weekly under the skin. The trial aims to assess the impact of survodutide on liver function and safety over a period of up to 7 years, with regular monitoring and assessments conducted throughout the study. [Extracted from the article]

A study conducted at the Second Affiliated Hospital of Chongqing Medical University in China explored the use of 131I and/or artificial liver support system (ALSS) in managing hyperthyroidism and liver failure. The research involved 74 patients with severe liver failure due to Graves' disease, divided into three groups receiving different treatments. Results showed that combining 131I and ALSS led to better outcomes in terms of thyroid and liver function compared to using ALSS alone. The study recommended prompt administration of 131I in cases of severe liver failure with hyperthyroidism to improve liver function and reduce mortality rates. [Extracted from the article]

Researchers at Samson Assuta Ashdod University Hospital conducted a case study on the efficacy of adding high doses of intravenous vitamin C to the combination therapy of atezolizumab and bevacizumab in treating unresectable hepatocellular carcinoma (HCC). The study involved a 68-year-old male patient with unresectable HCC who showed significant clinical and radiological improvements after the addition of intravenous vitamin C to his treatment regimen. This case study suggests that combining high-dose intravenous vitamin C with atezolizumab and bevacizumab may be a safe and effective treatment option for unresectable HCC, warranting further exploration through additional studies. [Extracted from the article]

A study conducted at Lomonosov Moscow State University focused on assessing liver function using hepatobiliary contrast agent-enhanced magnetic resonance imaging. The research analyzed data from 53 patients and found correlations between liver parenchyma signal intensity and various blood test parameters reflecting liver function. While the study confirmed the potential of using MRI to evaluate liver function, it did not support the effectiveness of using the liver parenchyma signal intensity to portal vein signal intensity ratio as an index. The findings suggest that MRI can be a valuable tool in assessing liver function. [Extracted from the article]

A systematic review and meta-analysis conducted by researchers at Qatar University evaluated the effectiveness of the Mediterranean diet in improving liver function in children and adolescents with metabolic dysfunction-associated steatotic liver disease (MASLD). The study analyzed five studies with a total of 308 participants and found that the Mediterranean diet was associated with moderate improvements in liver function, as indicated by reductions in liver enzymes. However, changes in body weight, lipid profile, and insulin resistance were small and insignificant. The researchers concluded that more randomized controlled trials are needed to further investigate these findings. [Extracted from the article]

A study conducted by researchers at Universitas Prima Indonesia explored the effects of nanoherbal extract of andaliman on liver function and histopathology in male wistar rats with streptozotocin-induced diabetes. The study found that there was no significant difference in liver function between the groups given andaliman and those that were not. However, there was a difference in liver histopathology, indicating that the groups given andaliman experienced liver degeneration. The researchers concluded that while andaliman has antioxidant effects that protect the liver, it also contains substances that can cause damage to liver cells. They recommended further research with more samples and analysis of the effects of specific compounds in andaliman on liver cells. [Extracted from the article]

A recent study conducted at the National Scientific Medical Center in Astana, Kazakhstan, investigated the impact of autologous bone marrow-derived mononuclear cell (BM-MNC) transplantation on patients with primary biliary cholangitis (PBC), a liver and immune system condition. Sixteen PBC patients participated in the study, and their BM-MNCs were harvested, cultivated, and infused back into their peripheral veins. The study found significant reductions in liver function tests after multiple transplantations, as well as changes in immune cell populations. These findings suggest potential therapeutic applications of BM-MNC transplantation in managing PBC and provide insights into the dynamics of immune cells associated with this treatment approach. [Extracted from the article]

A new report from the Iuliu Hatieganu University of Medicine and Pharmacy in Cluj-Napoca, Romania, explores the impact of CFTR modulator therapies on liver function in cystic fibrosis patients. The study conducted a systematic review of hepatic biomarkers and found mixed results for alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma glutamyltransferase (GGT) levels, with some studies reporting increases and others reporting decreases. However, lumacaftor/ivacaftor (LI) therapy was associated with significant reductions in GGT and alkaline phosphatase (AP) levels, while elexacaftor/ivacaftor/tezacaftor (ETI) therapy showed significant increases in bilirubin levels. The study emphasizes the need for more standardized research to better understand the effects of CFTR modulators on liver function in cystic fibrosis patients. [Extracted from the article]

Researchers at Mashhad University of Medical Sciences have published a study on the long-term association between HTLV1 infection and liver function and lipid indices. The study found that HTLV1 infection, a retrovirus prevalent in northeastern Iran, is associated with liver dysfunction and altered lipid profiles. The researchers measured serum levels of liver enzymes and calculated various lipid indices in 1116 participants, including healthy individuals and HTLV1-infected patients, over a 10-year follow-up period. The study revealed that HTLV1-infected patients had reduced visceral fat tissue and elevated levels of liver enzymes, indicating liver damage. These findings highlight the involvement of HTLV1 in liver pathology. [Extracted from the article]

A recent study conducted in Santa Cruz de Tenerife, Spain, explored the association between serum malondialdehyde (MDA) levels and lipid profile and liver function in patients with inflammatory bowel disease (IBD). MDA is a biomarker for oxidative stress and has been found to be elevated in patients with IBD. The study analyzed MDA levels in 197 IBD patients and found that MDA was significantly associated with male sex but not with other demographic characteristics or classic cardiovascular risk factors. Additionally, lipid profile abnormalities and liver disease were identified as the primary sources of elevated MDA in IBD patients. [Extracted from the article]

This document provides information about a clinical trial studying the use of AZA (azacytidine) in patients with graft-versus-host disease (GVHD). The trial aims to investigate the effects of AZA on gut stem cells by collecting blood samples at various time points after treatment. The study is in the early phase and is currently not recruiting participants. The eligibility criteria for the trial are outlined, and contact information for the primary investigator is provided. The document also includes administrative information about the trial, such as the study ID number and data monitoring committee. [Extracted from the article]

A recent study conducted at Baylor College of Medicine in Houston, Texas, examined the effects of the ketogenic diet on liver function. The ketogenic diet is commonly used as a therapy for patients with medically refractory epilepsy. The study found that during the initiation of the diet, some patients experienced acute changes in liver function tests, both in hepatocellular and cholestatic patterns. However, these changes were asymptomatic and reversible, and most patients were able to continue the diet with adjustments to medications or the addition of choline. The study suggests that while acute liver toxicity is rare, it should be monitored in patients starting the ketogenic diet. [Extracted from the article]

This article discusses a clinical trial, NCT06602622, that is studying the effects of changing HIV treatment on body weight. The trial will include patients who have developed metabolic syndrome after starting HIV treatment or antiretroviral therapy and have gained at least 10% of their body weight. Participants will be randomly assigned to either continue their current treatment or switch to another treatment. The study will evaluate changes in body weight, BMI, lipid profile, body composition, cardiovascular risk, kidney function, and neuropsychiatric disorders over a period of 48 weeks. The document outlines the procedures and methods for the trial, including medical interviews, informed consent, and various measurements and tests. The goal is to determine the impact of switching HIV medication regimens on weight and BMI. The trial is currently recruiting participants and is expected to be completed by November 2025. [Extracted from the article]

A recent study conducted by researchers at SRM Institute of Science and Technology in Tamil Nadu, India, explored the efficacy and safety of BoozLiv syrup as an add-on therapy for patients with alcoholic liver disease (ALD). The study involved 68 adult ALD patients who were randomized into two groups: one receiving standard therapy and the other receiving standard therapy along with BoozLiv syrup. The results showed that BoozLiv syrup, when used in conjunction with standard therapy, significantly reduced liver damage markers and improved liver function in ALD patients. The syrup was well-tolerated with only minor adverse effects reported. Further long-term studies are needed to validate these findings and establish BoozLiv as a potential therapeutic option for ALD. [Extracted from the article]

A recent study conducted in Lahore, Pakistan, explored the impact of cross-cutting psychiatric symptoms on the quality of life of individuals with Hepatitis B and C. The study found a high prevalence of depression, anxiety, anger, somatic symptoms, memory disturbances, and other associated psychiatric symptoms among participants. These symptoms were found to have a significant negative association with quality of life, social support, and resilience. The study highlights the need for healthcare counseling and support services for individuals diagnosed with Hepatitis B and C. [Extracted from the article]

A study conducted by researchers at Kerman University of Medical Sciences in Iran investigated the effects of methadone maintenance therapy on the body mass index (BMI) and various biochemical parameters of opioid use disorder patients over a period of three years. The study found that fasting blood glucose levels increased over time, while lipid profile variables remained unchanged. Liver function tests showed a significant decrease in alkaline phosphatase levels. The study concluded that methadone treatment can impact certain biochemical parameters, emphasizing the need to monitor these changes. [Extracted from the article]

A recent study conducted by researchers at the State University of New York (SUNY) in Brooklyn aimed to determine if cumulative organ function for more than 90 years is possible for transplanted kidneys and livers. The study included kidney and liver transplants from living or deceased donors aged 55 years and older. The findings showed that while only 2.7% of kidney grafts reached the 90-year cumulative organ function mark, 16.6% of liver grafts did. The study concluded that age alone should not exclude older kidney and liver donors from consideration for transplantation. [Extracted from the article]

A recent study conducted in Beijing, China explored the predictive value of immune inflammation combined with liver function hematological indicators for the metastasis of colorectal cancer. The study analyzed clinical data from 133 patients with colorectal cancer and found that certain immune inflammatory markers and liver function hematological indicators were independent predictors of colorectal cancer metastasis. The researchers constructed a nomogram prediction model that showed good accuracy and net benefit value in predicting metastasis. This study suggests that the nomogram based on immune inflammation and liver function hematological indicators has high predictive efficacy and potential clinical applications for patients with colorectal cancer. [Extracted from the article]

A study conducted by researchers at Nguyen Tat Thanh University in Ho Chi Minh City, Vietnam, explores the potential health benefits of cascara kombucha as a functional beverage. The study found that cascara kombucha effectively decreased free radicals, alpha-amylase, and lipase activity, suggesting its potential as an antioxidant and for modulating carbohydrate and lipid metabolism. In a mouse model, oral administration of cascara kombucha improved liver health, reduced fasting blood glucose levels, and lowered serum cholesterol content induced by a fat-enriched diet. The study concludes that cascara kombucha shows promise in addressing health issues caused by poor dietary habits and metabolic imbalances. [Extracted from the article]

A recent research study conducted in China examined the incidence, associated factors, and prognosis of liver dysfunction in children with community-acquired pneumonia. The study involved 4,623 hospitalized children with pneumonia, of which 12.8% (592) had liver dysfunction. The research found that young age and severe pneumonia were risk factors for liver dysfunction, and the recovery time for liver enzymes was not short. The study suggests that infants and children with severe pneumonia should receive closer follow-up. [Extracted from the article]

A new report discusses research findings on liver function, specifically focusing on the role of RNA splicing in metabolic dysfunction-associated steatotic liver disease (MASLD). RNA splicing is a crucial mechanism for gene expression and proteomic diversity. The review explores the regulation of RNA splicing in the liver and its impact on metabolic balance, detoxification, and protein synthesis. It also highlights how dysregulation of splicing can lead to liver diseases such as MASLD and discusses potential therapeutic approaches using antisense oligonucleotides (ASOs) to correct splicing errors. The dysregulation of splicing in liver diseases may also serve as a potential diagnostic marker for early identification of individuals at risk. [Extracted from the article]

A recent study conducted in Guangxi, People's Republic of China, focused on a rare condition called fistula caused by iliac aneurysm rupture into the inferior vena cava. The study found that heart failure and lower extremity edema were the most common symptoms, but this particular patient also experienced severe hepatic dysfunction. The researchers concluded that considering hepatic function is important in this condition, and that endovascular aortic repair (EVAR) is an effective treatment method. The study provides valuable insights into this rare condition and its treatment options. [Extracted from the article]

A study conducted by researchers at Capital Medical University in Beijing, China, aimed to investigate liver injury in pediatric patients with Acute Promyelocytic Leukemia (APL) and the effects of different treatments on liver function. The study analyzed data from 186 patients and found that 12.2% of patients experienced liver injury after treatment with arsenic. However, the majority of these cases were transient and occurred during the induction period of treatment. The study also found that the risk of liver injury associated with a specific treatment was not higher than that associated with another treatment. Further research is needed to explore whether a specific liver enzyme can be used as an index of liver injury in children. [Extracted from the article]

The article reports on a study from Universitas Lambung Mangkurat investigating the effects of heavy metal contamination on liver function in a rat model. Topics discussed include the impact of lead (Pb), cadmium (Cd), and mercury (Hg) on liver transaminase enzyme levels, the methodology of administering these metals to rats, and the finding that mercury exposure led to the highest levels of liver enzyme elevation, suggesting its greatest potential for liver toxicity.

A recent study conducted by researchers at the First Affiliated Hospital of Chongqing Medical University in China examined the association between ethylene oxide exposure and liver function in the adult population of the United States. Ethylene oxide is a reactive epoxy compound commonly used in various industries. The study analyzed data from the National Health and Nutrition Examination Survey (NHANES) from 2013 to 2016 and found that ethylene oxide exposure was significantly associated with changes in liver function indicators. The researchers concluded that further research is needed to explore these relationships. [Extracted from the article]

A study conducted at Shinshu University in Matsumoto, Japan, aimed to determine the minimum proportion of future liver remnant (pFLR) required for safe major hepatopancreatoduodenectomy (HPD). The study involved 48 major HPD patients and found that a pFLR of at least 45% is recommended to prevent severe post-hepatectomy liver failure (PHLF). Remnant liver function scores, particularly remnant ALICE, were also found to be good predictors of PHLF. The researchers concluded that major HPD may be considered in patients with good remnant liver function. [Extracted from the article]

Morphic Medical Inc. has been issued a patent for methods of assessing treatment with a gastrointestinal implant. The patent aims to identify individuals who are at risk of developing complications from treatment with gastrointestinal implants, such as gastrointestinal sleeves, which are used to treat metabolic disorders like type 2 diabetes and obesity. The methods involve measuring biomarkers in samples from individuals to determine their risk of complications and guide subsequent treatment decisions, including the removal of the implant. The patent addresses the need for non-surgical methods to treat metabolic disorders while minimizing complications. [Extracted from the article]

The article outlines liver function findings from the Department of Clinical Laboratory in a case report on neonatal lupus erythematosus (NLE) with liver function damage and cytomegalovirus colonization. It highlights the rarity of such cases and details the diagnosis process for a newborn male, which involved clinical symptoms, laboratory tests, auxiliary examinations, and family history, ultimately confirming NLE with liver function damage and cytomegalovirus colonization.

A study conducted at Guangzhou Medical University in China examined the use of secukinumab in the treatment of severe plaque psoriasis with abnormal liver function. The study found that secukinumab was effective and safe for patients with this condition, as evidenced by significant improvements in psoriasis severity, quality of life, and physician assessment scores. Importantly, no significant changes were observed in liver function, blood lipid profile, blood glucose level, or renal function during the treatment. This research provides valuable insights into the potential benefits of secukinumab therapy for individuals with severe plaque psoriasis and liver dysfunction. [Extracted from the article]

This document provides information about an ongoing clinical study (NCT06549062) that is investigating the use of venous blood and VAMS (volumetric absorptive microsampling) to measure the concentration of paracetamol and its metabolites in obese patients undergoing laparoscopic bariatric surgery. The study aims to determine if VAMS can be used as a patient-friendly alternative to venous blood sampling. The study will also assess liver function, pain scores, and the use of pain medication in both obese and non-obese patients. The study is currently recruiting participants and is expected to be completed by January 2025. [Extracted from the article]

The article discusses a new study highlighting the need for standardization in liver function tests (LFTs) to improve diagnostic accuracy. Topics discussed include the impact of pyridoxal-5-phosphate on ALT and AST assays, the variation in LFT profiles across laboratories, and the discrepancies in FIB-4 scores due to different testing methods.

The article presents the discussion on impact of removing the boxed hepatotoxicity warning and liver function testing requirements for ambrisentan on its use and monitoring compared to bosentan. Topics include changes in prescribing patterns, effects on liver function testing; and implications for clinician education on medication safety.

The article highlights the patent application number USPTO 20240252456 for "Oral Composition, Skin Cosmetic And Hair Cosmetic," filed by Shota Hayashi and colleagues on May 12, 2022. It also discusses the use of natural compounds in creating products for anti-metabolic syndrome, skin whitening, anti-aging, hair growth, and inflammation reduction, as well as the potential benefits of these compounds in improving liver function.

The article focuses on evaluating the impact of raspberry consumption on anthropometric indices and liver function tests in adults. Topics include the results of a meta-analysis of randomized control trials, the lack of significant effects on weight and liver function, and the need for further research with larger sample sizes.

A recent study conducted at Erasmus University Medical Center in Rotterdam, Netherlands, has found that a liver function test called LiMAx can predict the function of donor livers and the risk of complications in recipients. The study used a technique called abdominal normothermic regional perfusion (aNRP) to evaluate 18 donor livers that would have otherwise been discarded. The LiMAx test was successfully performed during aNRP and showed a correlation between LiMAx scores and liver function. This research suggests that the LiMAx test could be a valuable tool in personalized matching of donor livers for individual recipients, reducing post-transplant complications. [Extracted from the article]

A patent application has been published online by the US Patent and Trademark Office, titled "Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient." The application, filed by inventor Andreas Moraitis and assigned to Corcept Therapeutics Incorporated, describes methods for treating Cushing's syndrome, liver disorders, and other conditions without adverse effects on the liver. The methods involve administering a selective glucocorticoid receptor modulator (SGRM) called relacorilant, along with drugs that may cause liver toxicity, to reduce or prevent liver damage. The application also provides a list of drugs that may cause liver toxicity and can be used in conjunction with relacorilant. [Extracted from the article]